Pralsetinib data puts Blueprint on track for two FDA decisions this year

Blueprint moved a step closer to having two precision cancer therapies approved this year after announcing it started a rolling submission of an NDA for RET inhibitor pralsetinib along with updated Phase I/II data.

Blueprint Medicines Corp. (NASDAQ:BPMC) is a little more than a month away from its first FDA decision: avapritinib is under review to treat PDGFRA exon 18-mutant gastrointestinal stromal tumors (GIST) with a Feb. 14 PDUFA date. ...